City Zürich Job Type Full Time Location Switzerland - Zürich Function Category Client advisory / Relationship management Join us At UBS, we know that its our people, with their diverse skills, experiences and backgrounds, who drive
Since the legends reincarnation in 1994, A. Lange & Söhne has been one of the most respected and successful watch brands in the luxury sector. Our whole aim is to continue our tradition with new, outstanding
About the Company Interactive Brokers Group, Inc. (NASDAQ: IBKR), a member of the S&P 500, is a global financial services company headquartered in Greenwich, Connecticut, with offices in over 15 countries. Through its affiliates, Interactive Brokers provides
If you enjoy building relationships and helping develop innovative solutions while working in a fast-paced environment, then we have the role for you. Our advisors help clients achieve their financial goals by delivering the right solutions and services
Company Description At Swissquote, we’re all in. All in to shake things up. All in to build the bank people actually want to use. All in to make finance less boring — and a lot more
General information Legal entity GEODIS is a leading global logistics provider acknowledged for its expertise across all aspects of the supply chain. As a growth partner to its clients, GEODIS specializes in five lines of business:
Your area of responsibility As Vice President Investments, you will be responsible for supporting the team throughout the investment lifecycle, starting from sourcing and execution of transactions to post-closing value creation and asset management tasks all
At Alcon, were passionate about enhancing sight and helping people see brilliantly. With more than 25,000 associates, we innovate fearlessly, champion progress, and act swiftly to impact global eye health. We foster an inclusive culture, recognizing your
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)